In our study, patients with GRIN2A mutations in SKCM and IDH1, TP53, and ATRX mutations in GBMLGG have a better prognosis than wild-type patients, whereas patients with KRAS and TP53 mutations in PAAD have a worse prognosis (Supplementary Figure 7), and the π signature correlated positively or negatively with several oncogenic molecules (Figure 4(e)). Here, KRAS is linked to pancreatic adenocarcinoma.